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Abstract 
 
Atypical Hemolytic Uremic Syndrome (aHUS) is a severe renal disease which is 
associated with defective complement regulation caused by multiple factors. We 
previously described the deficiency of Factor H related proteins CFHR1 and CFHR3 as 
predisposing factor for aHUS. Here we identify in an extended cohort of 147 aHUS 
patients that 16 juvenile individuals (i.e. 11%) who either lacked the CFHR1/CFHR3 
completely (n = 14) or showed extremely low CFHR1/CFHR3 plasma levels (n = 2), are 
positive for Factor H (CFH) autoantibodies. The binding epitopes of all 16 analyzed 
autoantibodies were localized to the C-terminal recognition region of Factor H, which 
represents a hot spot for aHUS mutations. Thus we define a novel subgroup of aHUS, 
termed ‘DEAP’ HUS’ (DEficiency of CFHR proteins and CFH Autoantibody Positive) 
that is characterized by a genetic and an acquired factor. Therefore screening for both 
parameters is relevant in HUS patients and reduction of CFH autoantibody levels 
represents a therapeutic option. 
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Introduction 
 
The atypical form of hemolytic uremic syndrome (aHUS) is characterized by 
microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure (1). 
aHUS is associated with defective complement regulation. The complement system 
represents an innate immune defense system that eleminates invading microbes. 
Mutations in genes coding for complement regulators Factor H (CFH), membrane 
cofactor protein (MCP), Factor B (CFB), C3 and Factor I (CFI) (2-9) cause impaired 
regulation of the alternative pathway convertase C3bBb. This results in defective local 
complement control on host cell surfaces (10, 11). In addition, CFH gene conversion, 
deletion of the complement Factor H related genes CFHR1 and CFHR3 by nonallelic 
homologous recombination and the presence of CFH autoantibodies have been 
reported in aHUS patients (12-16).  
 
These diverse scenarios are responsible for ~50% of the reported cases, indicating 
that additional factors contribute to aHUS. On the surface of human cells multiple 
regulators control complement activation. Under physiological conditions defective 
function of one mutated protein is compensated by the additional regulators, which 
display redundant activities. This situation might explain the incomplete penetrance of 
the genetic mutations. We have recently shown that CFH autoantibodies of five patients 
bind to the C-terminus of CFH and reduce CFH-C3b interaction (16).  
 
In order to extend the understanding of the molecular basis of aHUS we 
determined the frequency of CFH autoantibodies in the Jena aHUS cohort and 
correlated the presence of CFH autoantibodies with CFHR1 and CFHR3 expression. 
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Materials and Methods 
This study was approved by the Research Ethics Committee of the Friedrich Schiller 
University, Jena, the University of Cologne, Germany and the Hospital for Sick Children, 
Toronto, Canada. 
 
Patients 
The cohort analyzed here represents an extended cohort 147 patients with atypical 
HUS of which 121 patients were recently reported (14). Informations to patients are 
summarized (supplementary information).  
 
Western Blot Analysis 
Plasma samples of all patients (not shown) and of members of three selected families 
were investigated by Western blotting (14). CFHR1 was detected using monoclonal 
antibody C18 and CFHR3 was detected with CFHR3 antiserum .   
 
Identification and domain mapping of CFH autoantibodies 
The binding domains of the CFH autoantibodies in CFH were determined by ELISA as 
described (16). Briefly, microtiter plates (Nunc, Wiesbaden, Germany) were coated with 
CFH fragments (17), incubated with plasma of the patients and CFH autoantibodies 
were detected with HRP-conjugated anti human IgG antibodies (Sigma-Aldrich, 
Taufkirchen, Germany).  
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Results and dicussion  
 
Frequency of CFH autoantibodies. Here we identify by ELISA in a cohort of 
147 aHUS patients 16 children (i.e. 11%) as positive for CFH autoantibodies (Table 1). 
CFH autoantibodies were completely absent in a control group of 100 healthy 
individuals thus indicating that CFH autoantibodies are associated with aHUS. Similar to 
the young age of the patients of the Jena cohort, the eight previously identified CFH 
autoantibody positive HUS patients (5 to 17 years) (15, 16) were also juvenile 
suggesting related mechanisms for autoantibody induction.  
 
Further analyses of the CFH autoantibody positive group revealed that by means of 
Western blotting the patients showed either the complete absence of CFHR1 and 
CFHR3 in plasma (14 patients) or displayed low, barely detectable levels of CFHR1 and 
CFHR3 (Table 1 and data not shown). The strong correlation between the occurrence of 
CFH autoantibodies and absence or reduction of CFHR1/CFHR3 in plasma suggests 
that this deficiency represents a risk factor for CFH autoantibody formation. The 
mechanism how a deficiency of these plasma proteins leads to the generation of CFH 
autoantibodies is currently unknown and requires further investigations. The 22 
CFHR1/CFHR3 deficient patients of the Jena cohort include 16 CFH autoantibody 
positive and six patients which have no autoantibodies to CFH. The frequency of the 
deficient group without CFH autoantibodies is 4% in this cohort and thus slightly higher 
than in the Jena and Newcastle control groups (2% each) (14) or in the Iowa-, 
Columbia- and Finish AMD study cohorts (2.7, 3.0 and 2.5% respectively (18). 
Concurrence of two risk factors in development of aHUS has been reported for 
combined mutations in either the CFI and the MCP genes (19) or for various CFH 
haplotypes (20). Here we report a new combination of two disease associated 
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conditions in predominantly juvenile aHUS patients, namely the presence of CFH 
autoantibodies and absence of CFHR1/CFHR3 in plasma. 
 
 
Family studies. Family studies were performed to analyze how autoantibodies to 
CFH or CFHR1/CFHR3 deficiency influences or predisposes to the disease. Three CFH 
autoantibody positive, CFHR1 and CFHR3 deficient patients and their family members 
were assayed for both parameters (Figure 1). In family A the patient (AII1) (Figure 1A) 
was positive for CFH autoantibodies (Figure 1D) and CFHR1 and CFHR3 proteins were 
absent in his plasma (Figure 1B, lane 2). The mother (AI2, lane 6), showed lower 
plasma levels of CFHR1 and CFHR3 proteins, indicating heterozygous deficiency. The 
other family members lacked CFHR1 and CFHR3 proteins which corresponds to 
homozygous deficiency. Genetic analyses confirmed homozygous CFHR1 and CFHR3 
deficiency for the patient (AII1), the healthy brother (AII2), the healthy sister (AII3) and 
the healthy father (AI1). The CFH gene was intact in all family members (data not 
shown). A similar scenario was observed for families B and C. In family B the patient, 
but no other relative was positive for CFH autoantibodies (Figure 1D). CFHR1 and 
CFHR3 proteins were absent in the plasma of the patient (BII1) and the unaffected 
healthy sister (BII2) (Figure 1B, lanes 8 and 9); but were detected in sera of the healthy 
mother and the father (Figure 1B, lanes 10 and 11). Genetic analyses confirmed that 
the patient and his sister were homozygous for the CFHR1/CFHR3 gene deletion. 
Similarly, in family C the aHUS patient was positive for CFH autoantibodies (Figure 1D) 
and CFHR1/CFHR3 proteins were absent. The remaining four healthy family members 
lacked CFH autoantibodies and also CFHR1/CFHR3 proteins in plasma (Figure 1B, 
lanes 13 to 17). Genetic analyses confirmed a homozygous deletion of CFHR1/CFHR3 
genes and non rearranged CFH genes for all members of this family (data not shown). 
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Thus, in each family the HUS patient was positive for CFH autoantibodies and deficient 
for CFHR1 and CFHR3. The chromosomal breakpoints in each case was located in the 
same chromosomal repeat region as recently described (14). All 11 members of the 
three families, who lacked CFH autoantibodies and showed either homozygous or 
heterozygous CFHR1/CFHR3 deficiency were healthy. Thus, these family studies 
demonstrate that CFH autoantibodies develop on a background of CFHR1 and CFHR3 
deficiency.  
 
We have previously localized the binding epitope of five CFH autoantibodies, 
derived from aHUS patients, two of which are also part of the Jena aHUS cohort, to the 
C-terminus of CFH. In addition these CFH autoantibodies inhibit the regulatory function 
of CFH at the cell surface (16). In order to define if this phenomenon holds true for the 
newly identified CFH autoantibodies their binding epitopes were also identified. 
 
CFH autoantibodies from each of the 16 patients bound to the C-terminal fragments 
of CFH, i.e. SCRs 15–20 and SCRs 19-20, but neither to SCRs 1–7, SCRs 11–15, 
SCRs 15-18 nor to SCRs 15-19 (supplementary Table I). Four CFH autoantibodies, also 
showed weak binding to a fragment representing SCRs 8–11 of CFH. This profile 
reveals that all 16 analyzed CFH autoantibodies bind preferentially within the C-terminal 
recognition region of CFH (21 - 25), which represents also a hot spot for aHUS 
associated mutations (9). This overlap suggests similar functional consequences for the 
CFH autoantibodies and for the genetic mutations, namely reduced cell recognition 
functions of CFH.  
 
In summary, we identify a new subgroup of aHUS patients who are deficient for 
CFHR1 and CFHR3 in plasma and positive for CFH autoantibodies. This deficiency may 
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favour development of specific autoantibodies which bind to the recognition region of 
CFH and likely block cell binding. It remains to be shown if disease progression of this 
new subgroup differs from that of other HUS patients e.g. patients with CFHR1/CFHR3 
deficiency and the absence of CFH autoantibodies or patients with CFH mutations. 
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Figure legends 
 
Figure 1: Family analysis: Deficiency of CFHR1 and CFHR3 in aHUS patients and 
their family members. (A) A pedigree is shown for each family. Black boxes: patients, 
open symbols: family members with homozygous CFHR1 and CFHR3 deletion, grey 
symbols: individuals with heterozygous CFHR1 and CFHR3 deficiency. Plasma of the 
patients or their healthy family members were separated by SDS-Page, transferred to a 
membrane and analyzed by Western blotting using a mAB which identifies the 
conserved C-termini of CFH (150 kDa) and the two differently glycosylated forms of 
CFHR1 and CFHR1 (42 and 37 kDa). For detection of CFHR3, antiserum reacting 
with different glycosylated forms of CFHR3 (45 kDa, multiple bands) was used. (B) 
Western blot analysis of plasma derived from individual family members demonstrated 
deficiency of CFHR1 in the aHUS patients (* lanes 2, 8, 13) and also in healthy relatives 
(lanes 3- 5, 9, 14-17). CFHR1 (α and β) are detected in plasma of a healthy control 
(lanes 1, 7, 12).  CFH is detected in all plasma samples. (C) Complete deficiency of 
CFHR3 is detected in the three aHUS patients (lanes 2, 8, 13) and several relatives 
(lanes 3-5; 9; 14-17) but CFHR3 is observed in the plasma of a healthy volunteer (lanes 
1, 7, 12) and of heterozygous relatives (lanes 6, 10 and 11). The band at 30 kDa in lane 
2 is unspecific. (D) CFH autoantibodiy levels were detected by ELISA. CFH 
autoantibodies (black bars) are present in serum of the patients (AII1, BII1 and CII1) but 
not of their relatives (dashed bars) and in plasma derived from controls (co, grey bars).. 
The dotted line represents the background level (OD450 0.35), i.e. highest absorbancy of 
plasma samples derived from 100 control individuals (see supplementary information).  
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Table 1 Frequency of CFH autoantibodies and CFHR1 and CFHR3 deficiency in the 
             Jena cohort  
  
 
n     
CFH 
autoantibodies
    n 
CFHR1/CFHR3
  deficiency 
  n  
aHUS patients   147 16   (11%)  22   (15%)  
controls  100  0    (0%) 2    (2%)  
 
 
 
Table I: Frequency of Factor H (CFH) autoantibodies in aHUS patients of the Jena 
cohort. The 16 patients who developed CFH autoantibodies, either lack 
CFHR1/CFHR3 completely in plasma (n = 14) or show extremely low levels of the two 
CFHR proteins (n = 2) as determined by Western blotting. The CFHR1 and CFHR3 
deficient group includes the 16 patients of the CFH autoantibody positive group and six 
deficient individuals who have no autoantibodies to CFH. No CFH autoantibodies were 
detected in the control group representing 100 healthy individuals. The mean 
absorbancy of all 100 control probes was OD 0.17 ± 0.1. The highest value determined 
for one sample of the control group was 0.35 OD, therefore the cut off for false positive 
was set to 0.35 OD. 
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Supplementary information 
 
Patients :  family analyses 
Patient 1 (family A) was diagnosed with aHUS at age 13 10/12, patient 2 (family B) was 
diagnosed with aHUS at age 7 2/12 and patient 3 (family C) at age 12. The initial sample 
assayed for the presence of CFH autoantibodies was taken at day of admission to the 
hospital prior to treatment. All three patients were treated with repeated plasmapheresis and 
their renal function recovered. Genetic deletion of CFHR1 and CFHR3 was analyzed as 
described and hybrid CFH/CFHR1 genes were excluded by sequencing genomic DNA 
(12). The sequence of the CFH (CFH), MCP (CD45) and Factor I (CFI), and Factor B 
(CFB) genes were analyzed for each patient. Except for a single amino acid exchange at 
position 950 Q to H in the CFH gene from patient AII1 no further disease associated 
mutation was identified. 
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Supplementary Figure 1: CFH autoantibody levels in aHUS 
 
 
 
Figure 1: CFH autoantibodies levels in aHUS patients. Autoantibody levels were 
determined by ELISA in serum of a Jena HUS cohort (147 aHUS patients)(not shown) and a 
control group (100 healthy volunteers). The autoantibody levels of the 22 CFHR1 and CFHR3 
deficient and the two low patients are indicated on the left. 16 samples (left upper panel 
indicated by filled rombi) were positive for CFH autoantibodies showed a mean value of OD 
0.77 ± 0.2, p < 0.00001). The other six CFHR1/CFHR3 deficient patients with an A < 0.35 
(mean OD 0.2 ± 0.1, p = 0.148) (left lower panel indicated by open rombi) were considered 
negative. The antibody levels of the remaining 125 aHUS patients, which express CFHR1 and 
CFHR3, was <OD 0.35. The mean absorbancy of all 100 control probes was OD 0.17 ± 0.1. 
46 representative samples of the control group are shown in the right panel (grey boxes). The 
highest value determined for one sample of the control group was 0.35 OD, therefore the cut 
off for false positive was set to 0.35 OD. Statistical analysis was performed using the 
Student’s T-test. 
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Supplementary Table 1: Localization of the binding domains of CFH autoantibodies 
in CFHR1 and CFHR3 deficient HUS patients 
 
 
 Patient # 
CFH 
fragments 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
SCRs 1–7 – – – – – – – – – – – – – – – – 
SCRs 8–11 (+) – – – – – (+) – (+) – – (+) – – – – 
SCRs 11–
15 
– – – – – – – – – – – – – – – – 
SCRs 15–
18 
– – – – – – – – – – – – – – – – 
SCRs 15–
19 
– – – – – – – – – – – – – – – – 
SCRs 15–
20 
+ + + + + + + + + + + + + + + + 
SCRs 19–
20  
+ + (+) + + + + + + + + + (+) + (+) + 
 
 
For domain mapping microtiter plates were coated with the indicated 
recombinant Factor H (CFH) fragments and probed with patient’s serum (16). 
Binding of autoantibodies to the indicated Factor H fragments was considered 
positive (+) for OD450 >0.35 A (reaching absorbancy up to 1.5). Low binding 
(+) is based on an absorbancy ranging from OD450 >0.2 to <0.3 and no binding 
(–) by an OD450 of <0.2.   
 
